VX-765: Selective Oral Caspase-1 Inhibitor for Inflammation and Pyroptosis Research

Executive Summary: VX-765 is a potent, orally available pro-drug that selectively inhibits caspase-1 (ICE), a central enzyme in inflammasome-mediated cytokine processing and pyroptosis (APExBIO, 2024). In vivo, VX-765 is converted to VRT-043198, which blocks IL-1β and IL-18 maturation without affecting TNFα or IL-6 (Johnson et al., 2020). This compound enables targeted study of pyroptotic cell death and cytokine release in macrophages and T cells. VX-765 shows efficacy in preclinical models of arthritis, skin inflammation, and HIV-associated CD4+ T-cell death. The selectivity and workflow stability of VX-765 position it as an indispensable tool for inflammation and cell death research (contrast: this article extends previous workflow-focused summaries by emphasizing molecular mechanism and selectivity).

Biological Rationale

Caspase-1 (interleukin-1 converting enzyme, ICE) is a key cysteine protease in the innate immune response. Upon activation by canonical inflammasomes, caspase-1 cleaves pro-IL-1β and pro-IL-18, releasing active cytokines that drive inflammation (Johnson et al., 2020). Caspase-1 also activates gasdermin D, forming membrane pores and initiating pyroptosis, a lytic form of programmed cell death observed in macrophages and lymphoid cells. Dysregulated caspase-1 activity is implicated in autoimmune, infectious, and neuroinflammatory diseases. Selective inhibition of caspase-1 with small molecules like VX-765 allows researchers to dissect the specific contributions of this pathway, separating effects on IL-1β/IL-18 from broader cytokine networks.

Mechanism of Action of VX-765

VX-765 is a pro-drug that is orally absorbed and metabolized in vivo to VRT-043198, its active form (APExBIO). VRT-043198 binds to the active site of caspase-1, competitively inhibiting its enzymatic activity. This prevents the cleavage of pro-IL-1β and pro-IL-18, blocking their secretion. Notably, VX-765 does not inhibit other inflammatory cytokines, such as IL-6, IL-8, TNFα, or IL-α, nor does it inhibit the related caspase family members at standard concentrations (contrast: this article updates on cross-caspase specificity). Selectivity arises from the molecular structure of VRT-043198, which fits the substrate recognition pocket unique to caspase-1/ICE-like proteases.

Evidence & Benchmarks

• VX-765 inhibits caspase-1 with nanomolar potency (IC₅₀ ≈ 0.8–1.0 μM in cell-based assays; buffered at pH 7.5) (APExBIO).
• In mouse models of collagen-induced arthritis, oral VX-765 significantly reduced paw swelling and serum IL-1β levels compared to controls (Johnson et al., 2020).
• In ex vivo HIV-infected lymphoid tissues, VX-765 prevented CD4+ T-cell pyroptotic death in a dose-dependent manner (≥50% reduction at 10 μM, 24 h incubation) (clarified here by direct cytokine and cell death readouts).
• VX-765 treatment in skin inflammation models reduced IL-1β and IL-18 release without altering TNFα or IL-6 secretion (tofacitinib.biz).
• Selective inhibition confirmed: VX-765 does not inhibit DPP8/9 or non-canonical inflammasome pathways in lymphocytes at tested doses (Johnson et al., 2020).

Applications, Limits & Misconceptions

VX-765 is widely used in preclinical models of autoimmune and infectious diseases, including rheumatoid arthritis, neuroinflammation, and HIV-associated cell death. Its oral bioavailability and selectivity for caspase-1 make it suitable for in vivo and ex vivo studies (this article clarifies optimized dosing and selectivity parameters compared to prior reviews).

Common Pitfalls or Misconceptions

• VX-765 does not inhibit non-canonical inflammasomes (e.g., NLRP3-independent, DPP8/9-mediated CARD8 activation).
• It does not block all caspase family members; cross-inhibition at standard concentrations is negligible.
• VX-765 is insoluble in aqueous buffers; improper solubilization can yield inconsistent dosing (APExBIO).
• Long-term storage in solution at ambient temperature causes degradation; use desiccated powder at -20°C.
• Clinical translation: Efficacy and safety in humans remain under investigation; animal and ex vivo results may not predict clinical outcomes.

Workflow Integration & Parameters

For enzyme inhibition assays, VX-765 is typically dissolved in DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL with ultrasonic) and diluted into buffered media (pH 7.5). Solutions should be prepared fresh or stored short-term at -20°C. Standard in vitro concentrations range from 0.1–50 μM, depending on cell type and model. For in vivo studies, oral dosing regimens are model-dependent (e.g., 25–50 mg/kg body weight per day in mice). Assays employ ELISA or multiplex cytokine arrays to measure IL-1β and IL-18 release, with parallel viability or cell death readouts to capture pyroptosis (workflow enhancements discussed here).

Conclusion & Outlook

VX-765 (A8238) from APExBIO provides a rigorously validated, selective tool for caspase-1 inhibition in inflammatory and cell death research. Its unique pharmacology enables precise dissection of IL-1β/IL-18 signaling and pyroptosis. As clinical studies progress, VX-765 will continue to shape our understanding of inflammasome biology, cytokine modulation, and translational opportunities in autoimmunity, infection, and neuroinflammation. For detailed protocols and batch-specific data, visit the VX-765 product page.